Cited by 467Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

A Hundred Years of Alzheimer's Disease Research

Open access
Hardy, John·2006·Neuron

Abstract

On the 100th anniversary of Alzheimer's lecture describing the clinicopathological entity which bears his eponym, this article reviews the major areas of progress in our understanding of the disease and outlines the many gaps still remaining. The progress toward effective mechanistic therapy is reviewed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuron.2006.09.016

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The amyloid hypothesis states that Aβ peptides lie upstream of all the pathological events occurring in AD, including NFT formation, synaptic dysfunction, and neuronal death.

    “The amyloid hypothesis states that Aβ peptides lie upstream of all the pathological events occurring in AD, including NFT formation, synaptic dysfunction, and neuronal death (Oddo et al., 2003b; Hardy, 2006).”

    From The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease (2011) · cites this paper as Hardy, 2006

    The passage labeled Abstract (page unavailable) describes amyloid deposition as central to the amyloid hypothesis and discusses Aβ toxicity and electrophysiological effects. It does not state that Aβ lies upstream of all AD pathology, specifically NFT formation, synaptic dysfunction, and neuronal death. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • Mitochondrial dysfunction and oxidative stress may encourage the development of amyloid plaques and NFTs.

    “mitochondrial dysfunction and oxidative stress may encourage the development of amyloid plaques and NFTs”

    From The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease (2011) · cites this paper as Hardy, 2006

    The passages on amyloid deposition and neurofibrillary tangles (labeled Abstract; no page supplied) discuss APP, presenilin, and MAPT mutations, but do not link mitochondrial dysfunction or oxidative stress to the development of either lesion. Searches for “mitochondrial,” “oxidative stress,” and “reactive oxygen species” found no passage addressing that proposed link. (LLM, conf=0.74)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 17

  1. [1]1. Adolfsson, R. ∙ Gottfries, C.G. ∙ Roos, B.E. ... Changes in the brain catecholamines in patients with dementia of Alzheimer type Br. J. Psychiatry. 1979; 135:216-223 Crossref PubMed Google Scholar
  2. [2]2. Alzheimer, A. Uber einen eigenartige Erkranung der Hirnrinde Allgemeine Zeitschrift fur Psychiatrie und Psychisch-Gerichtisch Medizin. 1907; 64:146-148 Google Scholar
  3. [3]3. Asai, M. ∙ Hattori, C. ∙ Szabo, B. ... Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase Biochem. Biophys. Res. Commun. 2003; 301:231-235 Crossref Scopus (153) PubMed Google Scholar
  4. [5]5. Atwood, C.S. ∙ Perry, G. ∙ Smith, M.A. Cerebral hemorrhage and amyloid-beta Science. 2003; 299:1014 Crossref PubMed Google Scholar
  5. [6]6. Bartus, R.T. Physostigmine and recent memory, effects in young and aged nonhuman primates Science. 1979; 206:1087-1089 Crossref PubMed Google Scholar
  6. [7]7. Beach, T. The history of Alzheimer's disease: three debates J. Hist. Med. Allied Sci. 1987; 42:327-349 Crossref Scopus (46) PubMed Google Scholar
  7. [9]9. Bielschowsky, M. Die Silberimprägnation der Achsencylinder Neurologisches Zentralblatt. 1902; 21:579-584 Google Scholar
  8. [10]10. Bird, T.D. ∙ Lampe, T.H. ∙ Nemens, E.J. ... Characteristics of familial Alzheimer's disease in nine kindreds of Volga German ancestry Prog. Clin. Biol. Res. 1989; 317:229-234 PubMed Google Scholar
  9. [12]12. Borchelt, D.R. ∙ Ratovitski, T. ∙ van Lare, J. ... Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins Neuron. 1997; 19:939-945 Full Text Full Text (PDF) Scopus (606) PubMed Google Scholar
  10. [13]13. Bowen, D.M. ∙ Smith, C.B. ∙ White, P. ... Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies Brain. 1976; 99:459-496 Crossref PubMed Google Scholar
  11. [15]15. Brion, J.P. ∙ Passareiro, H. ∙ Nunez, J. ... Mise en evidence de la immunologique de la protein tau au lesions de degeneresescence neurofibrillaire de la maladie Alzheimer Arch Biol. (Brux). 1985; 95:229-235 Google Scholar
  12. [16]16. Cai, X.D. ∙ Golde, T.E. ∙ Younkin, S.G. Release of excess amyloid beta protein from a mutant amyloid beta protein precursor Science. 1993; 259:514-516 Crossref PubMed Google Scholar
  13. [17]17. Chartier-Harlin, M.C. ∙ Crawford, F. ∙ Houlden, H. ... Early onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene Nature. 1991; 353:844-846 Crossref PubMed Google Scholar
  14. [18]18. Chartier-Harlin, M.C. ∙ Parfitt, M. ∙ Legrain, S. ... Related Articles, Links Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease, analysis of the 19q13.2 chromosomal region Hum. Mol. Genet. 1994; 3:569-574 Crossref PubMed Google Scholar
  15. [19]19. Chen, F. ∙ Hasegawa, H. ∙ Schmitt-Ulms, G. ... TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity Nature. 2006; 440:1208-1212 Crossref Scopus (164) PubMed Google Scholar
  16. [20]20. Citron, M. Beta-secretase inhibition for the treatment of Alzheimer's disease–promise and challenge Trends Pharmacol Sci. 2004; 25:92-97 Full Text Full Text (PDF) Scopus (146) PubMed Google Scholar
  17. [22]22. Citron, M. ∙ Teplow, D.B. ∙ Selkoe, D.J. Generation of amyloid beta protein from its precursor is sequence specific Neuron. 1995; 14:661-670

Cited by

Sorted by citations

Authors
Hardy, J.
Affiliations
National Institutes of Health (US)
Corresponding author
Hardy, John
Venue
Neuron
Publisher
Elsevier BV
Published
2006-10
Volume
52
Issue
1
Pages
3-13
ISSN
0896-6273 (ISSN-L)
OpenAlex
W2166625407
Cited by
467
References
26
Citations by year
2026: 11 · 2025: 11 · 2024: 14 · 2023: 18 · 2022: 17 · 2021: 22 · 2020: 21 · 2019: 16 · 2018: 29 · 2017: 14 · 2016: 26 · 2015: 29 · 2014: 24 · 2013: 33 · 2012: 34
FWCI
3.13
Type
journal article
Language
en
Open access
Locations
  • Neuron (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • National Institutes of Health
  • National Institute on Aging
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, clinicopathological diagnosis, pathogenesis, therapeutic target
MeSH terms
Alzheimer Disease, Animals, Humans, Research, Research Design, History, 20th Century, History, 21st Century

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review